Advanced Esophageal Cancer: Pembrolizumab plus Chemotherapy as First-line Therapy

被引：0
|
作者：
Franke, Katharina
机构：
来源：
ZEITSCHRIFT FUR GASTROENTEROLOGIE | 2021年 / 59卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1255 / +
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Zhu, Youwen
    Liu, Kun
    Ding, Dong
    Zhou, Yangying
    Peng, Libo
    ADVANCES IN THERAPY, 2022, 39 (06) : 2614 - 2629
  • [2] Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis
    Youwen Zhu
    Kun Liu
    Dong Ding
    Yangying Zhou
    Libo Peng
    Advances in Therapy, 2022, 39 : 2614 - 2629
  • [3] Cost-Effectiveness of Pembrolizumab Plus Chemotherapy as First-Line Therapy for Advanced Oesophageal Cancer
    Wu, Meiyu
    Qin, Shuxia
    Wang, Liting
    Tan, Chongqing
    Peng, Ye
    Zeng, Xiaohui
    Luo, Xia
    Yi, Lidan
    Wan, Xiaomin
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [4] Cost-effectiveness analysis of pembrolizumab plus chemotherapy versus chemotherapy as the first-line treatment for advanced esophageal cancer
    Ye, Zhuo-Miao
    Xu, Zhe
    Wang, Hao-Lun
    Wang, Ying-Yuan
    Chen, Ze-Chang
    Zhou, Qin
    Li, Xiang-Ping
    Zhang, Ying-Ying
    CANCER MEDICINE, 2023, 12 (05): : 6182 - 6189
  • [5] Pembrolizumab plus chemotherapy as first-line treatment for advanced biliary tract cancer
    Slater, Susanna
    Cunningham, David
    LANCET, 2023, 401 (10391): : 1826 - 1827
  • [6] Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
    Kato, K.
    Sun, J-M.
    Shah, M. A.
    Enzinger, P. C.
    Adenis, A.
    Doi, T.
    Kojima, T.
    Metges, J-P.
    Li, Z.
    Kim, S-B.
    Cho, B. C. Chul
    Mansoor, W.
    Li, S-H.
    Sunpaweravong, P.
    Maqueda, M. A.
    Goekkurt, E.
    Liu, Q.
    Shah, S.
    Bhagia, P.
    Shen, L.
    ANNALS OF ONCOLOGY, 2020, 31 : S1192 - S1193
  • [7] First-line pembrolizumab plus chemotherapy in Japanese patients with advanced/metastatic esophageal cancer from KEYNOTE-590
    Kojima, Takashi
    Hara, Hiroki
    Tsuji, Akihito
    Yasui, Hisateru
    Muro, Kei
    Satoh, Taroh
    Ogata, Takashi
    Ishihara, Ryu
    Goto, Masahiro
    Baba, Hideo
    Nishina, Tomohiro
    Han, Shirong
    Sakata, Tomoko
    Yatsuzuka, Naoyoshi
    Doi, Toshihiko
    Kato, Ken
    ESOPHAGUS, 2022, 19 (04) : 683 - 692
  • [8] First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.
    Li, Zhigang
    Sun, Yubei
    Ye, Feng
    Ma, Dong
    Yin, Xianli
    Zhuang, Wu
    Yuan, Xianglin
    Qin, Shukui
    Zhang, Yiping
    Gu, Kangsheng
    Zhao, Kuaile
    Xiao, Juxiang
    Cheng, Ying
    Bai, Yuxian
    Luo, Suxia
    Wang, Liwei
    Wang, Cailian
    Cui, Yi
    Mei, Lingling
    Shen, Lin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [9] Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone as First-Line Therapy for NSCLC
    Gadgeel, Shirish
    Gandhi, Leena
    Borghaei, Hossein
    Socinski, Mark A.
    Gubens, Matthew A.
    Stevenson, James
    Sequist, Lecia V.
    Yang, James Chih-Hsin
    Papadimitrakopoulou, Vassiliki
    Bourque, Jennifer
    Bachman, Robert D.
    Ge, Joy Yang
    Im, Ellie
    Patnaik, Amita
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S428 - S428
  • [10] Pembrolizumab plus chemotherapy for first-line treatment of advanced triple-negative breast cancer
    Haiderali, Amin
    Huang, Min
    Pan, Wilbur
    Akers, Katherine G.
    Maciel, Dylan
    Frederickson, Andrew M.
    FUTURE ONCOLOGY, 2024, 20 (22) : 1587 - 1600
12345